Assessment of Proteomic Measures Across Serious Psychiatric Illness.

Assessment of Proteomic Measures Across Serious Psychiatric Illness. Clin Schizophr Relat Psychoses. 2017;11(2):103-112 Authors: Schulz SC, Overgaard S, Bond DJ, Kaldate R Abstract The diagnoses of serious psychiatric illnesses, such as schizophrenia, schizoaffective disorder, and bipolar disorder, rely on the subjective recall and interpretation of often overlapping symptoms, and are not based on the objective pathophysiology of the illnesses. The subjectivity of symptom reporting and interpretation contributes to the delay of accurate diagnoses and limits effective treatment of these illnesses. Proteomics, the study of the types and quantities of proteins an organism produces, may offer an objective biological approach to psychiatric diagnosis. For this pilot study, we used the Myriad RBM Discovery Map 250+ platform to quantify 205 serum proteins in subjects with schizophrenia (n=26), schizoaffective disorder (n=20), bipolar disorder (n=16), and healthy controls with no psychiatric illness (n=23). Fifty-seven analytes that differed significantly between groups were used for multivariate modeling with linear discriminant analysis (LDA). Diagnoses generated from these models were compared to SCID-generated clinical diagnoses to determine whether the proteomic markers: 1) distinguished the three disorders from controls, and 2) distinguished between the three disorders. We found that a series of binary classification models including 8...
Source: Clinical Schizophrenia and Related Psychoses - Category: Psychiatry Tags: Clin Schizophr Relat Psychoses Source Type: research